Title: Measuring medicine prices, availability,
1- Measuring medicine prices, availability,
- affordability and price components
- Alexandra Cameron
- Department of Essential Medicines and
Pharmaceutical Policies - World Health Organization
-
- November 2008
2WHO/HAI Project on Medicine Prices Availability
- improve the availability and
- affordability essential medicines
- Outcome of the WHO/public interest NGOs
Roundtable on Pharmaceuticals - Develop a reliable methodology for collecting and
analysing price and availability data across
healthcare sectors and regions in a country - Price transparency survey data on a freely
accessible website allowing international
comparisons - Provide guidance on pricing policy options and
monitoring their impact
3WHO/HAI standard methodology
- Survey tool to measure
- medicine prices
- medicine availability
- affordability of treatments
- components in the supply chain
- 1st edition launched at WHA 2003
- About 60 surveys conducted to date
- 2nd edition launched at WHA 2008
- adjustments to methodology
- practical advice based on surveys
- new guidance on international comparisons,
- policy options, advocacy regular monitoring
- additional tools and resources
4Medicine price and availability surveys to date
using WHO/HAI methodology
Completed or nearing completion
Underway
5How is the survey conducted?
- Trained data collectors visit a sample of
"medicine outlets" and record information on the
price and availability of selected medicines - Data on government procurement prices are also
collected - During medicine outlet visits, data are recorded
on hard copy Medicine Prices Data Collection
forms - At the end of fieldwork, completed forms are
entered into the electronic survey Workbook by
data entry personnel - The Workbook automatically generates analyses of
the survey data - Medicine price components are also identified by
tracking medicines through the supply chain and
identifying add-on costs
6What medicines are surveyed?
- 50 medicines
- 30 pre-determined by WHO/HAI to enable
international comparisons (14 global medicines
and 16 regional medicines) - 20 selected nationally for local importance
- Predetermined dose forms strengths,
recommended pack sizes - For each medicine, two products are surveyed
- Originator brand
- Lowest-priced generic equivalent (at facility)
7Where are data collected from?
- Patient price and availability data
- collected by data collectors visiting a sample of
medicine outlets in up to 4 sectors - public sector - health centres
- private sector - retail pharmacies
- 1-2 other sectors e.g. dispensing doctors
-
- Government procurement prices
- Centralised system collect from procurement
office or Central Medical Store - Decentralised at outlet level
8How is the sample of medicine outlets selected?
- Data is collected in 6 regions of the country
("survey areas") - Area 1 capital city
- 5 other regions within 1 days travel of capital,
randomly selected - In each survey area
- the main public hospital 4 public outlets,
randomly selected from those within a 3 hours
drive of the main hospital, are selected - the private sector outlet closest to each public
outlet is selected - The other sector medicine outlet closes to each
public sector outlet is selected
9Sampling frame
10Survey structure
11Data entry, quality assurance analysis
- Training workshop pilot test for data
collectors and supervisors - At outlet visit, data are recorded onto the
Medicine Prices Data Collection Form. Form
checked that day by supervisor and verified in
20 of outlets - At the end of fieldwork, all completed forms are
entered into the Excel Workbook by trained data
entry personnel - Data are entered twice and checked for errors
- Automated data checker identifies possible errors
- An additional data quality control check is
conducted by HAI or WHO before posting on the
website
12How are data analyzed?
- Availability of outlets where medicine was
found on the day of data collection - Price median local prices expressed as ratios to
international reference prices - Medicine Price Ratio (MPR)
median local unit price -
International reference
unit price - MSH international reference prices used recent
procurement prices offered by not-for-profit
suppliers to developing countries for
multi-source generic equivalent products. - Medicine must be found in at least 4 outlets for
MPR to be calculated - Price comparisons innovator brand and lowest
priced generics public, private and other (e.g.
mission) sectors districts/states/provinces,
countries - Affordability how many days wages would the
lowest paid government worker need to spend to
pay for treatment
13Price Components
- The add-on costs that are applied to medicines as
they move through the supply chain, from
manufacturer to patient - Examples insurance freight costs, port
inspection charges, handling charges, import
duties, import, wholesale retail mark-ups,
VAT/GST, dispensing fees - The amount of charge is often variable depending
on whether the medicine is - Imported or locally manufactured
- Innovator brand or generic
- Sold in the public or private sector
- Crucial to understanding why prices are high and
what policy options can be considered - An integral part of the Medicine Prices survey
14Price components are analysed by stage of the
supply chain
15Price components methodology
- 2 parts
- Central level data collection on national
policies that affect pharmaceutical prices - Collected through interviews with pharmacists,
wholesalers, importers, Ministry of Health,
Ministry of Trade, Customs office, etc. - Identification of the actual price components of
selected medicines as they move along the supply
chain. - Identified by tracking 5-7 medicines backwards
through the supply chain, starting from the final
patient price - At each stage (retailer, wholesaler etc) the
charges applied to the medicine are recorded
16Price components data analysis
- Data are entered into the electronic survey
Workbook standard analyses are automatically
generated - Price components are analysed by
- cumulative per cent mark-up how much greater a
certain price is above the MSP - contribution of each stage to the final price
- Comparisons by sector, region, medicine type
(e.g. originator vs. generic, import vs. local)